ABT-263
Navitoclax (ABT-263) is an orally bioavailable small molecule that potently inhibits Bcl-2, Bcl-xL, and Bcl-w (Ki<1 nM), inducing apoptosis. It is widely used in cancer research, demonstrating antitumor activity in both in vitro cellular assays and in vivo xenograft models for studying programmed cell death mechanisms.
Product Specifications
CAS Number
923564-51-6
Product Name Alternative
Navitoclax
Field of Research
Cell Biology, Neuroscience, Stem Cell & Developmental Biology
Purity
>98%
Bioactivity
Bcl-2 family inhibitor, Senolytic agent
Form
Powder
Solubility
Soluble in DMSO (up to 25 mg/ml)
Smiles
C (C1=C (CCC (C) (C) C1) C2=CC=C (Cl) C=C2) N3CCN (CC3) C4=CC=C (C (NS (=O) (=O) C5=CC (S (C (F) (F) F) (=O) =O) =C (N[C@H] (CCN6CCOCC6) CSC7=CC=CC=C7) C=C5) =O) C=C4
Molecular Formula
C47H55ClF3N5O6S3
Molecular Weight
974.6
Storage Conditions
-20°C
Notes
For research use only.
Other Product Names
4-[4-[[2- (4-chlorophenyl) -5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[ (1R) - 3- (4-morpholinyl) -1-[ (phenylthio) methyl]propyl]amino]-3-[ (trifluoromethyl) sulfonyl]-phenyl]sulfonyl]-benzamide
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog